Cited 0 time in
TRESK channel as a potential target to treat T-cell mediated immune dysfunction
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Han, Jaehee | - |
| dc.contributor.author | Kang, Dawon | - |
| dc.date.accessioned | 2022-12-27T05:03:50Z | - |
| dc.date.available | 2022-12-27T05:03:50Z | - |
| dc.date.issued | 2009-12-25 | - |
| dc.identifier.issn | 0006-291X | - |
| dc.identifier.issn | 1090-2104 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/26071 | - |
| dc.description.abstract | In this review, we propose that TRESK background K+ channel could serve as a potential therapeutic target for T-cell mediated immune dysfunction. TRESK has many immune function-related properties. TRESK is abundantly expressed in the thymus, the spleen, and human leukemic T-lymphocytes. TRESK is highly activated by Ca2+, calcineurin, acetylcholine, and histamine which induce hypertrophy, whereas TRESK is inhibited by immunosuppressants, Such as cyclosporin A and FK506. Cyclosporine A and FK506 target the binding site of nuclear factor of activated T-cells (NFAT) to inhibit calcineurin. Interestingly, TRESK possesses an NFAT-like docking site that is present at its intracellular loop. Calcineurin has been found to interact with TRESK via specific NFAT-like docking site. When the T-cell is activated, calcineurin can bind to the NFAT-clocking site of TRESK. The activation of both TRESK and NFAT via Ca2+-calcineurin-NFAT/TRESK pathway could modulate the transcription of new genes in addition to regulating several aspects of T-cell function. (C) 2009 Elsevier Inc. All rights reserved. | - |
| dc.format.extent | 4 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | - |
| dc.title | TRESK channel as a potential target to treat T-cell mediated immune dysfunction | - |
| dc.type | Article | - |
| dc.publisher.location | 미국 | - |
| dc.identifier.doi | 10.1016/j.bbrc.2009.10.076 | - |
| dc.identifier.wosid | 000272650800005 | - |
| dc.identifier.bibliographicCitation | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, v.390, no.4, pp 1102 - 1105 | - |
| dc.citation.title | BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | - |
| dc.citation.volume | 390 | - |
| dc.citation.number | 4 | - |
| dc.citation.startPage | 1102 | - |
| dc.citation.endPage | 1105 | - |
| dc.type.docType | Review | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Biophysics | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Biophysics | - |
| dc.subject.keywordPlus | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | - |
| dc.subject.keywordPlus | POTASSIUM CHANNELS | - |
| dc.subject.keywordPlus | K+ CHANNEL | - |
| dc.subject.keywordPlus | ION CHANNELS | - |
| dc.subject.keywordPlus | MULTIPLE-SCLEROSIS | - |
| dc.subject.keywordPlus | CALCIUM-DEPENDENCE | - |
| dc.subject.keywordPlus | LYMPHOCYTES | - |
| dc.subject.keywordPlus | ACTIVATION | - |
| dc.subject.keywordPlus | CALCINEURIN | - |
| dc.subject.keywordPlus | EXPRESSION | - |
| dc.subject.keywordAuthor | Calcineurin | - |
| dc.subject.keywordAuthor | KCNK18 protein | - |
| dc.subject.keywordAuthor | Immune system disease | - |
| dc.subject.keywordAuthor | Immunosuppressive agents | - |
| dc.subject.keywordAuthor | Lymphocytes | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
